Visugromab clinical trials
Also written CTL-002.
How each study uses visugromab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the visugromab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
CatalYm GmbH (6)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses visugromab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 FailureRecruitingPhase 2CatalYm GmbHNCT07219459Written as Visugromab RDE (recommended dose for expansion)
- Visugromab in Cachexia International TrialRecruitingPhase 2/3CatalYm GmbHNCT07112196Written as Visugromab (CTL-002)
- Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLCRecruitingPhase 2CatalYm GmbHNCT07246863Written as Visugromab RDE (recommended dose for expansion)
- Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLCRecruitingPhase 2CatalYm GmbHNCT07098988Written as Visugromab
- First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)Active, not recruitingPhase 1/2CatalYm GmbHNCT04725474Written as visugromab (CTL-002)
- Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder CancerCompletedPhase 2CatalYm GmbHNCT06059547Written as Visugromab (CTL-002)
Codes
What other systems call visugromab · ClinicalTrials.gg INT017422
- UNII (FDA) NX3NW9MM9WVISUGROMABOne source FDA
- NCI Thesaurus C179558VisugromabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NX3NW9MM9W | VISUGROMAB | One source FDA |
| NCI Thesaurus | C179558 | Visugromab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.